Trends & Forecasts

Experts come together to discuss the chemistry of solubility and the drug delivery solutions of the future for dealing with poorly soluble compounds.

The original goal of 'Obamacare' was to increase access to health insurance, but has it worked?

With an approaching patent cliff in biologics, are we be about to see a rise in litigation?

PhRMA explain why the US Elections are important for the pharma industry.

It's Trump or Clinton for President. But what are the implications for pharma?

Costs of failing to communicate can cost you collaboration and investment.

Have Mylan been their own worst enemy with an imprudent pricing decision?

Emma Walmsley is chosen as GlaxoSmithKline's new CEO.

Richard Bergstrom has resigned from EFPIA - who will replace him?

Critics say a report from the UN on access to medicines ignores the real word industry